---
document_datetime: 2025-11-23 07:07:28
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/cotronak.html
document_name: cotronak.html
version: success
processing_time: 0.040789
conversion_datetime: 2025-12-28 02:13:54.458571
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Cotronak

[RSS](/en/individual-human-medicine.xml/66589)

##### Withdrawn

This medicine's authorisation has been withdrawn

ribavirin

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

The marketing authorisation for Cotronak has been withdrawn at the request of the marketing authorisation holder.

## Product information

01/03/2004

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

## Product details

Name of medicine Cotronak Active substance ribavirin International non-proprietary name (INN) or common name ribavirin Therapeutic area (MeSH) Hepatitis C, Chronic Anatomical therapeutic chemical (ATC) code J05AB04

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Cotronak is indicated for the treatment of chronic hepatitis C and must only be used as part of a combination regimen with peginterferon alfa-2b or interferon alfa-2b. Cotronak monotherapy must not be used.

## Authorisation details

EMA product number EMEA/H/C/000247 Marketing authorisation holder

Schering-Plough Europe

SP Europe Rue de Stalle, 73 B-1180 Bruxelles Belgium

Marketing authorisation issued 07/05/1999 Revision 4

**This page was last updated on** 01/03/2004

## Share this page

[Back to top](#main-content)